Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, open-label, 2-arm phase IIb/III Trial for Graft-versus-host disease (Prevention) in bone marrow transplantations

Next Previous
Search
Trial Profile

A multi-center, open-label, 2-arm phase IIb/III Trial for Graft-versus-host disease (Prevention) in bone marrow transplantations

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 26 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leukocyte-cell-therapy-Enlivex-Therapeutics (Primary)
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Enlivex Therapeutics

    • Most Recent Events

    • 25 Feb 2020 According to Enlivex Therapeutics media release, study is expected to start in 2020
    • 19 Nov 2018 According to Enlivex Therapeutics media release, study is expected to start in Q4 2019
    • 28 Jan 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top